TKI258 in Castrate Resistant Prostate Cancer

Summary

The goal of this clinical research study is to learn if a decrease in the levels of prostate specific antigen (PSA) may be linked with the status of prostate cancer that has spread to the bones. Researchers also want to learn how changes in your blood PSA level might affect the rebuilding of healthy bones while you are being treated with TKI258 for prostate cancer.

Timeline

Start

2010-04-07

Primary completion

2017-06-12

Completion

2017-06-12

Drugs

Indications